Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov ID: NCT00266240

Public ClinicalTrials.gov record NCT00266240. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind Study to Determine the Effect of GK Activator (2) on Efficacy (HbA1c), Safety, Tolerability and Pharmacokinetics in Patients With Type 2 Diabetes Mellitus

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral GK Activator (2), compared to placebo, in patients with type 2 diabetes mellitus. The anticipated time on study treatment is less than 3 months, and the target sample size is 100-500 individuals.

Study identification

NCT ID
NCT00266240
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
267 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
30 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2005 (Type not available)
Primary completion
May 2007 (Actual)
Completion
May 2007 (Actual)
Last update posted
Nov 2, 2016

2005 – 2007

United States locations

U.S. sites
19
U.S. states
14
U.S. cities
19
Facility City State ZIP Site status
Not listed Tucson Arizona 85723 —
Not listed Pine Bluff Arkansas 71603 —
Not listed Chula Vista California 91911 —
Not listed Spring Valley California 91978 —
Not listed West Hills California 91307 —
Not listed Hollywood Florida 33021 —
Not listed Atlanta Georgia 30308 —
Not listed Binghamton New York 13901 —
Not listed Fayetteville North Carolina 28304 —
Not listed Statesville North Carolina 28625 —
Not listed Winston-Salem North Carolina 27103 —
Not listed Springdale Ohio 45246 —
Not listed Oklahoma City Oklahoma 73112 —
Not listed Medford Oregon 97504 —
Not listed Beaver Pennsylvania 15009 —
Not listed Tipton Pennsylvania 16684 —
Not listed Mt. Pleasant South Carolina 29464 —
Not listed Plano Texas 75093 —
Not listed Renton Washington 98055 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00266240, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 2, 2016 · Synced Oct 31, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00266240 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →